Navigation Links
Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
Date:7/24/2012

SAN FRANCISCO, July 24, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that the first patient has been enrolled in a Phase 2 clinical study of NKTR-181, a new, first-of-its-kind, opioid analgesic candidate. NKTR-181 is a novel mu-opioid agonist molecule designed to have a slow rate of entry into the brain to reduce the attractiveness of the molecule as a target of abuse and to reduce other CNS-mediated side effects, such as sedation and respiratory depression. The Phase 2 study will utilize a double-blind, placebo-controlled, randomized withdrawal study design to assess the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee. Approximately 200 patients will be randomized to receive either NKTR-181 or placebo in the study.

"We are extremely pleased to be part of this Phase 2 clinical study of NKTR-181 in chronic pain patients," said Jeffrey Gudin, MD, Director of Pain Management and Palliative Care, Englewood Hospital & Medical Center and Clinical Instructor of Anesthesiology at Mt. Sinai School of Medicine. "NKTR-181 exhibited highly differentiated properties in its Phase 1 development, which include slow penetration across the blood-brain barrier into the CNS. This slow rate of entry may allow us to effectively address pain while reducing some of the most troubling opioid CNS effects such as euphoria, sedation, and respiratory depression. NKTR-181 represents a potential paradigm shift in the way we think about opioid analgesia."

NKTR-181 is an NCE (new chemical entity) which was created using Nektar's proprietary small molecule polymer conjugate technology and its potential differentiating properties are inherent to the design of the new molecule. As a new molecular structure, NTKR-181 does not rely on a formulation approach, which is a com
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Today DePuy Synthes Companies ... angle plating systems featuring its proprietary variable angle ... screw trajectory to match patient anatomy and fracture ... bone. The systems are being introduced in conjunction ... (AOFAS) and the International Federation of Foot & ...
(Date:9/19/2014)... /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... report firstly reviews the basic information of ... manufacturing technology. The report then explores global ... listing their product specification, capacity, Production value, ...
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
... March 5, 2012   Synteract , Inc., a full-service contract ... MBA, as senior vice president of sales and marketing and ... president, global project management, to support growth in the company ... Barr, COO Stewart Bieler, and CFO Patrik Jeanmonod on the ...
... Checkpoint Surgical has received the CE mark ... intraoperative neuroprotective stimulator that helps surgeons locate, identify ... to facilitate nerve preservation and repair. ... certification demonstrates that a medical device meets rigorous ...
Cached Medicine Technology:Synteract Expands Executive Roles to Support Growth 2Synteract Expands Executive Roles to Support Growth 3Checkpoint Surgical Receives CE Mark 2
(Date:9/21/2014)... PITTSBURGH, PA (PRWEB) September 21, 2014 ... energy boost without having to consume sugary, foul-tasting energy ... also did not always just want to drink plain, ... this alternative energy booster." , He developed ENERG CHEWING ... also assist with weight loss. The formula contains nutritious ...
(Date:9/21/2014)... 2014 "I want to help people ... but haven’t the money for chiropractors," said an inventor ... such a product for myself." , The Stretch is ... the thigh muscles and align the spine properly. It ... discomfort of pinched nerves. Compact and easy to use, ...
(Date:9/21/2014)... 2014 Best Cheap Hosting USA, one ... Arvixe, Bluehost and GreenGeeks are the best Reseller hosting ... good reseller hosting supplier. Actually, these companies have outperformed ... customer support. People can get the best web hosting ... , According to the manager, reseller hosting is a ...
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk ... trendy items. Recently, the company has unveiled its 2014 ... and elegant wedding gowns, Angeldress.co.uk wants to make sure ... an easy way. Its high quality vintage wedding outfits ... off to 62% off. , Online shopping is becoming ...
(Date:9/21/2014)... 2014 “Cluster headaches are sometimes called ... difficult to resolve,” said Steve Young of Ew Publishing; ... a pain that is more intense.” , “It should ... headaches, or migraines, that medical research is pointing to ... he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2
... Ga., April 30 Immucor, Inc. (Nasdaq: ... systems to the blood transfusion industry, today announced that ... and Merrill Lynch 2009 Health Care Conference in New ... webcast. The Company,s presentation is scheduled for Tuesday, ...
... - Clinic operations revenue ... sales revenue increases 173%,VANCOUVER, April 30 /PRNewswire-FirstCall/ - CRH ... of $6,655,342 for the year ended 2008 compared to ... operations revenue increased 100% to $6,047,590 for the year ...
... proven calcium channel blocker, angiotensin receptor blocker and ... In a clinical trial, Exforge HCT demonstrated significantly ... to all dual combinations of its components - ... medications to help control their blood pressure and ...
... /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") ... markets specialty pharmaceutical products in China, today announced ... Company on investor communications best-practices in the U.S. ... China Pharma, stated, "Our decision to hire ICR ...
... added benefit from cholesterol-reducing agent , , , THURSDAY, ... cells to release cholesterol might prove effective in ... new study suggests. , George Washington University researchers ... found that the treatment restored cholesterol outflow from ...
... HealthSouth Corporation (NYSE: HLS ) today announced it ... Conference on May 12-14, 2009, at the Four Seasons Hotel ... Executive Vice President and Chief Financial Officer John Workman will ... (7:55 a.m. CT). The presentation will be webcast live and ...
Cached Medicine News:Health News:CRH Medical reports year end results 2Health News:CRH Medical reports year end results 3Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 2Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 3Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 4Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 5Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 6Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 7Health News:China Pharma Holdings, Inc. Retains Global Investor Communications Team 2
... Design Holds The Lens Securely During ... Blades Keep The Optic From Being ... Over Release Of The Optic.,Wide Jaw ... During Insertion.,Reusable, Autoclaveable, Made In The ...
... Unique In-Line Footplates Are Turned 90 ... The Diamond Blade While Incising Tissue. ,Special ... Blade Depth Penetration.,Pre-Set Blade Extension Settings ... Retraction And Full Extension.,1mm Wide Snub ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Medicine Products: